^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DCSZ11

    i
    Other names: DCSZ11
    Associations

    News

    Trials
    Company:
    DynamiCure Biotech
    Drug class:
    CD93 inhibitor
    Related drugs:
    Associations

    News

    Trials
    13d
    DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Jun 2027
    Enrollment open • Trial initiation date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • HER-2 negative • BRAF V600 • ALK rearrangement • ALK fusion • ROS1 fusion • ROS1 rearrangement • NTRK fusion
    |
    DCSZ11
    9ms
    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=320, Recruiting, DynamiCure Biotechnology | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • Kimmtrak (tebentafusp-tebn) • DCSZ11
    9ms
    A Prospective Single-Arm Clinical Study of DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=9, Not yet recruiting, West China Hospital
    New P1/2 trial
    |
    DCSZ11
    over1year
    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=257, Recruiting, DynamiCure Biotechnology | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • DCSZ11
    over2years
    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=251, Recruiting, DynamiCure Biotechnology | N=96 --> 251
    Enrollment change • Metastases
    |
    Keytruda (pembrolizumab) • DCSZ11
    over2years
    DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, DynamiCure Biotechnology | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    DCSZ11
    almost3years
    DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Not yet recruiting, DynamiCure Biotechnology
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    DCSZ11
    over3years
    DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, DynamiCure Biotechnology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    DCBY02 • DCSZ11